Orasure Technologies (OSUR)
NASDAQ:OSUR
Want to see OSUR full AI Analyst Report?
OSUR Stock Chart & Stats
$2.38
-$0.09(-2.38%)
At close: 4:00 PM EST
$2.38
-$0.09(-2.38%)
Day’s Range― - ―
52-Week Range$2.08 - $3.82
Previous CloseN/A
Volume226.53K
Average Volume (3M)771.42K
Market Cap
$212.30M
Enterprise Value$228.89M
Total Cash (Recent Filing)$199.28K
Total Debt (Recent Filing)$13.20M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 11, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding71,965,614
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue1.99
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda-3.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$118.29M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Zero DebtA $199M cash balance and no debt provides durable financial flexibility to fund R&D, complete integration of small acquisitions, sustain share repurchases, and cover operating losses while new products ramp. This liquidity materially lengthens the runway for multi-quarter execution.
Near‑term Product Pipeline With FDA SubmissionsTwo regulatory submissions targeting midyear launches represent structural revenue diversification beyond legacy COVID volumes. If approved, these products access large, durable end markets (CT/NG TAM >$1.5B) that can sustainably lift volumes and improve scale economics over multiple years.
Manufacturing Consolidation And Operational LeverageNear‑complete consolidation into a single facility and internalizing volume reduces per‑unit costs and provides material operating leverage. With current utilization near 30%, successful volume recovery will convert fixed‑cost savings into lasting gross margin expansion as throughput increases.
Bears Say
Steep Revenue Decline And Return To LossesA severe decline in scale has swung margins deeply negative and overwhelmed cost structure. Restoring durable profitability requires sustained top‑line recovery; absent that, fixed costs and restructuring charges risk keeping returns depressed for multiple quarters.
Negative Operating And Free Cash Flow; Multi‑year Breakeven TargetRecent cash burn and negative free cash flow create ongoing funding sensitivity despite a large cash stockpile. A 2027 breakeven target implies execution risk across product approvals, commercial execution, or further capital actions if revenue recovery slips versus plan.
Reliance On Public‑health Funding And Regulatory Timing RiskRevenue recovery depends partly on external public‑health procurement cycles and successful, timely FDA reviews. Funding disruptions and regulatory delays can materially postpone demand realization, leaving capacity underutilized and pressure on margins until durable orders materialize.
Orasure Technologies News
OSUR FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $3.82 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is $212.30M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is Aug 11, 2026 which is in 97 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on May 06, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.09.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.21.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 71,965,614 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
OSUR Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 14.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.53%
12-Months-Change
Fundamentals
Return on Equity
-18.58%
Trailing 12-Months
Asset Growth
-15.95%
Trailing 12-Months
Company Description
Orasure Technologies
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.
OSUR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights clear progress on strategic priorities: revenue slightly beat guidance midpoint, meaningful improvement in gross margins year-over-year, strong cash position with no debt, two significant FDA submissions targeting midyear launches, tangible international expansion (Canada launch, nearshoring in Africa) and early success integrating BiMedomics. Offsetting these positives are sizable operating losses and negative operating cash flow, a multi-year timeline to return to operating cash flow breakeven (target 2027), lingering funding-related headwinds in international public-health markets, regulatory timing uncertainty for new product launches, and under-utilized capacity that makes margin improvement contingent on revenue ramp. Overall, the call conveys cautious optimism grounded in a solid balance sheet and promising near-term product catalysts but tempered by execution risk and the need for top-line recovery to fully realize margin and cash-flow benefits.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
5.37% Insiders
16.41% Mutual Funds
5.93% Other Institutional Investors
60.11% Public Companies and
Individual Investors